When we examined NOS2 expression in 3 breast cancer patient groups (all subtypes, basal-like, and ER−/PR−) we found that high NOS2 expression was associated with decreased overall survival (confirming previous reports11) (Fig. 4A). This evidence concerns the gene NOS2 and breast carcinoma.